SanegeneBio to Present Interim Phase 2 Results of SGB-9768 at ASN Kidney Week 2026

BOSTON, SHANGHAI, and SUZHOU – October 13, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced that interim Phase 2 results of SGB-9768, an experimental siRNA medicine targeting complement C3, have been accepted for poster presentation at the American Society of Nephrology (ASN) Kidney Week 2026, October 22-25, 2026, in Denver, CO.

The interim Phase 2 results in patients with IgA nephropathy, C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), including the UPCR, eGFR and safety endpoints, will be presented for the first time during ASN Kidney Week 2026.

ASN Kidney Week 2026 Presentation Details

Title: Interim Phase 2 Results of SGB-9768, a Liver-Targeted GalNAc-siRNA Targeting Complement C3, in IgA Nephropathy, C3 Glomerulopathy, and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Presenter: Professor Minghui Zhao, Peking University First Hospital

Presentation Time: October 22, 2026 10:00 AM-12:00 PM

Session: Late-Breaking Research Posters [LB-PO]

Poster Board #: TH-PO1259

About SGB-9768

SGB-9768 is a GalNAc-conjugated experimental RNAi-based medicine designed to silence C3 mRNA in hepatocytes, thereby inhibiting complement activation. It is being developed for the treatment of complement-mediated kidney diseases and hematologic disorders, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), IC-MPGN, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In Phase 1 clinical trials, SGB-9768 has demonstrated significant, dose-dependent, sustained reduction in serum C3 levels and inhibition of alternative pathway activity following a single-dose subcutaneous administration, supporting the potential for infrequent dosing. With a favorable safety profile and greater durability than comparator molecules, SGB-9768 has the potential to become a best-in-class RNAi therapeutic for complement-mediated diseases. SGB-9768 is currently being evaluated in a Phase 2 clinical study and has received U.S. FDA Orphan Drug Designation for the treatment of C3G and IC-MPGN.

About SanegeneBio

SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, increasing the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune, cardiovascular, obesity and metabolic diseases. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage with us on LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “could,” “potential,” “is/are likely to,” “will,” “plan,” “intend,” “aim,” “expect,” “anticipate,” “believe,” “hope,” “estimate,” “project,” “forecast,” “continue,” “target,” and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements. 

These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.

Medical Information

This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.